Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer

Neha Chopra(Schrodinger (United States)), Nicholas C. Turner(Institute of Cancer Research)

Nature Communications

May 29, 2020

10.1038/s41467-020-16142-7

Cited by 258

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

|The Lancet Oncology|2016|1.8k

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

|New England Journal of Medicine|2015|1.6k

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

|Annals of Oncology|2021|1.4k

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

|New England Journal of Medicine|2018|1.3k

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

|Journal of Clinical Oncology|2018|925